

# Effective Treatments for Opioid Use Disorder: A Systematic Review



Jill M. Moore, PhD, RN, CNE  
Lambda Sigma Chapter

Indiana State University, Terre Haute, IN United State of America

# Opioid Use Disorder Background

- Access
- Opioid Addiction
- Pathophysiology
- Outcomes – Health, Financial, and Societal
- Impact



# Opioid Use Disorder Methodology

- Review completed in summer of 2017
- Databases
- Search
- Yield



# Opioid Use Disorder Results

- Replacement Therapy
- Behavioral Therapy
- The combination of these two modalities is called Medication Assisted Treatment (MAT)



# Opioid Use Disorder

## Methadone

- Classification - full opioid receptor agonist
- Slow onset of action and long half-life
- Daily dosing – 80 to 120 mg
- Side effects
- Treatment retention rates



# Opioid Use Disorder

## Buprenorphine

- Classification - partial opioid receptor agonist
- Moderate onset of action and long half-life
- Daily dosing – 2 to 32 mg
- Side effects
- Treatment retention rates



# Opioid Use Disorder

## Naltrexone

- Classification - opioid antagonist
- Moderate onset of action and short half-life
- Daily dosing – 50 mg
- Side effects
- Treatment retention rates



# Opioid Use Disorder Discussion

- Methadone



- Buprenorphine



- Extended Release Naltrexone





# Opioid Use Disorder Implications

- Choice of replacement therapy should be individualized
- People with an opioid use disorder should be encouraged to participate in behavioral therapy
- Access to treatment
- Treatment advancements



# References

- American Nurses Association. (n.d.). *Medicated assisted treatment (MAT) - It's not giving drug to addicts*. Retrieved from <http://www.nursingworld.org/DocumentVault/OccupationalEnvironment/Substance-Use-Disorder/MAT-for-Opiate-Dependence.pdf>
- American Society of Addiction Medicines. (2015). *Opioid addiction 2016 facts & figures*. Retrieved from <https://www.asam.org/docs/default-source/advocacy/opioid-addiction-disease-facts-figures.pdf>
- Birnbaum, H. G., White, A. G., Schiller, M., Waldman, T., Cleveland, J. M. & Roland., C. L. (2011). Societal cost of prescription opioid abuse, dependence, and misuse in the United States. *Pain Medicine*, 12, 657–667. doi:10.1111/j.1526-4637.2011.01075.x
- Disley, E., Mulcahy, A. W., Pardal, M., Rubin, J., & Ruggeri, K. (2013). Development of a framework to estimate the cost of opioid dependence. Retrieved from [http://www.rand.org/pubs/research\\_reports/RR406.html](http://www.rand.org/pubs/research_reports/RR406.html)
- Kampman, K., & Jarvis, M. (2015). American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. *Journal of Addiction Medicine*, 9(5), 358–367. doi:10.1097/adm.0000000000000166
- Kunøe, N., Lobmaier, P., Ngo, H., & Hulse, G. (2012). Injectable and implantable sustained release naltrexone in the treatment of opioid addiction. *British Journal of Clinical Pharmacology*, 77(2), 264–271. doi:10.1111/bcp.12011
- National Institute of Health. National Institute on Drug Abuse. (2015). Prescription and over-the-counter medications. <https://www.drugabuse.gov/publications/drugfacts/prescription-over-counter-medications>
- National Institute of Health. National Institute on Drug Abuse. (2016). *Effective treatments for opioid addictions*. Retrieved from <https://d14rmgtrwzf5a.cloudfront.net/sites/default/files/opioidaddictiontreatment.pdf>



# References

- Nielsen, S., Degenhardt, L., Larance, B., Gowing, L., Kehler, C., & Lintzeris, N. (2014). Opioid agonist treatment for pharmaceutical opioid dependent people. *Cochrane Database of Systematic Reviews*. doi:10.1002/14651858.cd011117
- Parrino, M. (2013). Impact of opioid dependence on society. *Global Addiction Association*. Retrieved from <http://www.globaladdiction.org/position-statement-9.php>
- Saxon, A. J., Hser, Y., Woody, G., & Ling, W. (2013). Medication-assisted treatment for opioid addiction: Methadone and buprenorphine. *Journal of Food And Drug Analysis*, 21(4), S69–S72. doi:10.1016/j.jfda.2013.09.037
- Substance Abuse and Mental Health Services Administration. (2016). Opioids. Retrieved from <https://www.samhsa.gov/atod/opioids>
- Tetraut, J. M., & Fiellin D. A. (2012). Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals. *Drugs*, 72(2), 217–228. doi:10.2165/11597520-000000000-00000
- United Nations Office on Drugs and Crime. (2013). *Opioid overdose: Preventing and reducing opioid overdose mortality*. Retrieved from <http://www.unodc.org/docs/treatment/overdose.pdf>
- United Nations Office on Drugs and Crime. (2015). *World drug report 2015*. Retrieved from [http://www.unodc.org/documents/wdr2015/WDR15\\_Opiates.pdf](http://www.unodc.org/documents/wdr2015/WDR15_Opiates.pdf)
- Whelan, P. J., & Remski, K. (2012). Buprenorphine vs methadone treatment: A review of evidence in both developed and developing worlds. *Journal of Neurosciences in Rural Practice*, 3(1), 45–50. doi:10.4103/0976-3147.91934
- Younger, J. W, Chu, L. F, D'Arcy, N., Trott, K., Jastrzab, L. E., & Mackey, S. C. (2011). Prescription analgesics rapidly change the human brain. *Pain*, 152(8), 1803–1810. doi:10.1016/j.pain.2011.03.028

